Skip to main content

Articles

Page 17 of 39

  2. To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, and immune infiltrates.

    Authors: Tao Jiang, Jinpeng Shi, Zhengwei Dong, Likun Hou, Chao Zhao, Xuefei Li, Beibei Mao, Wei Zhu, Xianchao Guo, Henghui Zhang, Ji He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Chunyan Wu and Caicun Zhou
    Citation: Journal of Hematology & Oncology 2019 12:75
    Content type: Research Published on:

  3. During the 1970s, a Na+-independent, ouabain-insensitive, N-ethylmaleimide-stimulated K+-Cl− cotransport mechanism was identified in red blood cells for the first time and in a variety of cell types afterward. Du...

    Authors: A. P. Garneau, S. Slimani, L. E. Tremblay, M. J. Fiola, A. A. Marcoux and P. Isenring
    Citation: Journal of Hematology & Oncology 2019 12:74
    Content type: Review Published on:

  4. Double/triple-hit lymphomas (DHL/THL) account for 5–10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression. Despite the poor prognosis of DHL, ...

    Authors: Weiping Li, Shiv K. Gupta, Weiguo Han, Ryan A. Kundson, Sara Nelson, Darlene Knutson, Patricia T. Greipp, Sherine F. Elsawa, Eduardo M. Sotomayor and Mamta Gupta
    Citation: Journal of Hematology & Oncology 2019 12:73
    Content type: Rapid communication Published on:

  5. Acute myeloid leukemia (AML) patients with a high allelic burden of an internal tandem duplication (ITD)-mutated FMS-like Tyrosine Kinase-3 (FLT3) have a dismal outcome. FLT3ITD triggers the proliferation of the ...

    Authors: Maria Solovey, Ying Wang, Christian Michel, Klaus H. Metzeler, Tobias Herold, Joachim R. Göthert, Volker Ellenrieder, Elisabeth Hessmann, Stefan Gattenlöhner, Andreas Neubauer, Dinko Pavlinic, Vladimir Benes, Oliver Rupp and Andreas Burchert
    Citation: Journal of Hematology & Oncology 2019 12:72
    Content type: Research Published on:

  6. Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2). In c...

    Authors: Hui Hua, Qingbin Kong, Hongying Zhang, Jiao Wang, Ting Luo and Yangfu Jiang
    Citation: Journal of Hematology & Oncology 2019 12:71
    Content type: Review Published on:

  7. Glyphosate is the most widely used herbicide in the USA and worldwide. There has been considerable debate about its carcinogenicity. Epidemiological studies suggest that multiple myeloma (MM) and non-Hodgkin l...

    Authors: Lei Wang, Qipan Deng, Hui Hu, Ming Liu, Zhaojian Gong, Shanshan Zhang, Zijun Y. Xu-Monette, Zhongxin Lu, Ken H. Young, Xiaodong Ma and Yong Li
    Citation: Journal of Hematology & Oncology 2019 12:70
    Content type: Research Published on:

  9. As information on incidence, risk factors, and outcome of acute leukemia (AL) relapse after unmanipulated haploidentical stem cell transplantation (haplo-SCT) is scarce, a retrospective registry study was perf...

    Authors: Simona Piemontese, Ariane Boumendil, Myriam Labopin, Christoph Schmid, Fabio Ciceri, William Arcese, Yener Koc, Zafar Gulbas, Johanna Tischer, Benedetto Bruno, Depei Wu, Didier Blaise, Dietrich Beelen, Giuseppe Irrera, Annalisa Ruggeri, Mohamed Houhou…
    Citation: Journal of Hematology & Oncology 2019 12:68
    Content type: Research Published on:

  10. Small cell lung cancer (SCLC) is one of the deadliest cancer types in the world. Despite the high response rate to frontline platinum-containing doublets, relapse is inevitable for the majority of patients and...

    Authors: Yaru Tian, Xiaoyang Zhai, Anqin Han, Hui Zhu and Jinming Yu
    Citation: Journal of Hematology & Oncology 2019 12:67
    Content type: Review Published on:

  11. The chromosomal rearrangements of the mixed-lineage leukemia gene MLL (KMT2A) have been extensively characterized as a potent oncogenic driver in leukemia. For its oncogenic function, most MLL-fusion proteins ...

    Authors: Krzysztof Brzezinka, Ekaterina Nevedomskaya, Ralf Lesche, Michael Steckel, Ashley L. Eheim, Andrea Haegebarth and Carlo Stresemann
    Citation: Journal of Hematology & Oncology 2019 12:66
    Content type: Research Published on:

  12. Personalized and risk-adapted treatment strategies in multiple myeloma prerequisite feasibility of prospective assessment, reporting of targets, and prediction of survival probability in clinical routine. Our ...

    Authors: Dirk Hose, Susanne Beck, Hans Salwender, Martina Emde, Uta Bertsch, Christina Kunz, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Jérôme Moreaux and Anja Seckinger
    Citation: Journal of Hematology & Oncology 2019 12:65
    Content type: Research Published on:

  13. Inflammation has long been accepted as a key component of carcinogenesis. During inflammation, inflammasomes are potent contributors to the activation of inflammatory cytokines that lead to an inflammatory cas...

    Authors: Shengchao Xu, Xizhe Li, Yuanqi Liu, Yu Xia, Ruimin Chang and Chunfang Zhang
    Citation: Journal of Hematology & Oncology 2019 12:64
    Content type: Review Published on:

  15. Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies. However, the translation of the existing achievements into the treat...

    Authors: Jianshu Wei, Xiao Han, Jian Bo and Weidong Han
    Citation: Journal of Hematology & Oncology 2019 12:62
    Content type: Review Published on:

  16. Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually re...

    Authors: Dwight H. Owen, Michael J. Giffin, Julie M. Bailis, Marie-Anne Damiette Smit, David P. Carbone and Kai He
    Citation: Journal of Hematology & Oncology 2019 12:61
    Content type: Review Published on:

  17. Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor prognosis, and its treatment remains a challenge due to few targeted medicines and high risk of relapse, metastasi...

    Authors: Qing Xie, Zhijie Yang, Xuanmei Huang, Zikang Zhang, Jiangbin Li, Jianhua Ju, Hua Zhang and Junying Ma
    Citation: Journal of Hematology & Oncology 2019 12:60
    Content type: Research Published on:

  18. Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric an...

    Authors: Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan and Xingxing Zang
    Citation: Journal of Hematology & Oncology 2019 12:59
    Content type: Review Published on:

  19. Among all malignant tumors that threaten human health, virus-related tumors account for a large proportion. The treatment of these tumors is still an urgent problem to be resolved. The immune system is the “gu...

    Authors: Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma and Peng Wu
    Citation: Journal of Hematology & Oncology 2019 12:58
    Content type: Review Published on:

  20. Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the pote...

    Authors: Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Xiao Han, Qingming Yang, Zhiqiang Wu and Weidong Han
    Citation: Journal of Hematology & Oncology 2019 12:57
    Content type: Case report Published on:

  21. α3β1 integrin is a promising cancer biomarker and drug target. We previously identified a 9-amino-acid cyclic peptide LXY30 for detecting α3β1 integrin on the surface of live tumor cells. This study was undert...

    Authors: Wenwu Xiao, Weijie Ma, Sixi Wei, Qianping Li, Ruiwu Liu, Randy P. Carney, Kevin Yang, Joyce Lee, Alan Nyugen, Ken Y. Yoneda, Kit S. Lam and Tianhong Li
    Citation: Journal of Hematology & Oncology 2019 12:56
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:83

  23. Immunotherapies have led to substantial changes in cancer treatment and have been a persistently popular topic in cancer research because they tremendously improve the efficacy of treatment and survival of ind...

    Authors: Pengfei Zhao, Li Li, Xiaoyue Jiang and Qin Li
    Citation: Journal of Hematology & Oncology 2019 12:54
    Content type: Review Published on:

  24. The tumor microenvironment (TME) is an essential intrinsic portion of hepatocellular carcinoma (HCC) for the regulation of its origination, development, invasion, and metastasis. As emerging components of the ...

    Authors: Qin Wu, Lingyun Zhou, Duoduo Lv, Xia Zhu and Hong Tang
    Citation: Journal of Hematology & Oncology 2019 12:53
    Content type: Review Published on:

  25. Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cell...

    Authors: Eishiro Mizukoshi and Shuichi Kaneko
    Citation: Journal of Hematology & Oncology 2019 12:52
    Content type: Review Published on:

  26. Acute myeloid leukemia (AML) is a malignant tumor of the immature myeloid hematopoietic cells in the bone marrow (BM). It is a highly heterogeneous disease, with rising morbidity and mortality in older patient...

    Authors: Yan Liu, Zhiheng Cheng, Yifan Pang, Longzhen Cui, Tingting Qian, Liang Quan, Hongyou Zhao, Jinlong Shi, Xiaoyan Ke and Lin Fu
    Citation: Journal of Hematology & Oncology 2019 12:51
    Content type: Review Published on:

  28. Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated extraordinary efficacy in B cell malignancy therapy and have been approved by the US Food and Drug Administration for diffuse large B cell...

    Authors: Yingxi Xu, Qian Liu, Mengjun Zhong, Zhenzhen Wang, Zhaoqi Chen, Yu Zhang, Haiyan Xing, Zheng Tian, Kejing Tang, Xiaolong Liao, Qing Rao, Min Wang and Jianxiang Wang
    Citation: Journal of Hematology & Oncology 2019 12:49
    Content type: Research Published on:

  29. The importance of early cancer diagnosis and improved cancer therapy has been clear for years and has initiated worldwide research towards new possibilities in the care strategy of patients with cancer using t...

    Authors: Petra Bankó, Sun Young Lee, Viola Nagygyörgy, Miklós Zrínyi, Chang Hoon Chae, Dong Hyu Cho and András Telekes
    Citation: Journal of Hematology & Oncology 2019 12:48
    Content type: Review Published on:

  30. Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembroliz...

    Authors: Sen Yang, Zhe Zhang and Qiming Wang
    Citation: Journal of Hematology & Oncology 2019 12:47
    Content type: Review Published on:

  31. PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agent...

    Authors: Yuanyuan Yang, Xiaolong Zhang, Fangzhen Lin, Mengshang Xiong, Dongmei Fan, Xiangfei Yuan, Yang Lu, Yuewen Song, Yizi Zhang, Mu Hao, Zhou Ye, Yanjun Zhang, Jianxiang Wang and Dongsheng Xiong
    Citation: Journal of Hematology & Oncology 2019 12:46
    Content type: Research Published on:

  32. Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing r...

    Authors: Chao Zhang, Natasha B. Leighl, Yi-Long Wu and Wen-Zhao Zhong
    Citation: Journal of Hematology & Oncology 2019 12:45
    Content type: Review Published on:

  33. Limited data is available to guide the choice of the conditioning regimen for patients with acute myeloid leukemia (AML) undergoing transplant with persistent disease.

    Authors: Francesco Saraceni, Myriam Labopin, Arne Brecht, Nicolaus Kröger, Matthias Eder, Johanna Tischer, Hélène Labussière-Wallet, Hermann Einsele, Dietrich Beelen, Donald Bunjes, Dietger Niederwieser, Tilmann Bochtler, Bipin N. Savani, Mohamad Mohty and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2019 12:44
    Content type: Research Published on:

  35. Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for severa...

    Authors: Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery and Haitao Zhao
    Citation: Journal of Hematology & Oncology 2019 12:42
    Content type: Review Published on:

  36. Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the pas...

    Authors: Hongbing Ma, Iyer Swaminathan Padmanabhan, Simrit Parmar and Yuping Gong
    Citation: Journal of Hematology & Oncology 2019 12:41
    Content type: Review Published on:

  37. Successful treatment for acute myeloid leukemia (AML) remains challenging. Inhibiting immune checkpoint to enhance anti-tumor response is an attractive strategy for effective leukemia therapeutics. CD73 is a r...

    Authors: Yaxian Kong, Bei Jia, Chenchen Zhao, David F. Claxton, Arati Sharma, Charyguly Annageldiyev, Joseph S. Fotos, Hui Zeng, Robert F. Paulson, K. Sandeep Prabhu and Hong Zheng
    Citation: Journal of Hematology & Oncology 2019 12:40
    Content type: Research Published on:

  38. The Philadelphia (Ph) chromosome, resulting from the t(9;22)(q34;q11) translocation, can be found in chronic myeloid leukemia (CML) as well as in a subset of acute lymphoblastic leukemias (ALL). The deregulate...

    Authors: Simona Soverini, Renato Bassan and Thomas Lion
    Citation: Journal of Hematology & Oncology 2019 12:39
    Content type: Review Published on:

  39. Breast cancer is the most common malignancy in women all over the world. Genetic background of women contributes to her risk of having breast cancer. Certain inherited DNA mutations can dramatically increase t...

    Authors: Zeinab Safarpour Lima, Mostafa Ghadamzadeh, Farzad Tahmasebi Arashloo, Ghazaleh Amjad, Mohammad Reza Ebadi and Ladan Younesi
    Citation: Journal of Hematology & Oncology 2019 12:38
    Content type: Review Published on:

  40. Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence. Accumulating evidence shows that CD73-expressing ...

    Authors: Xiao-Lu Ma, Min-Na Shen, Bo Hu, Bei-Li Wang, Wen-Jing Yang, Li-Hua Lv, Hao Wang, Yan Zhou, An-Li Jin, Yun-Fan Sun, Chuan-Yan Zhang, Shuang-Jian Qiu, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang…
    Citation: Journal of Hematology & Oncology 2019 12:37
    Content type: Research Published on:

  41. Interferon alpha (IFNa) monotherapy is recommended as the standard therapy in polycythemia vera (PV) but not in chronic myeloid leukemia (CML). Here, we investigated the mechanisms of IFNa efficacy in JAK2V617...

    Authors: Claudia Schubert, Manuel Allhoff, Stefan Tillmann, Tiago Maié, Ivan G. Costa, Daniel B. Lipka, Mirle Schemionek, Kristina Feldberg, Julian Baumeister, Tim H. Brümmendorf, Nicolas Chatain and Steffen Koschmieder
    Citation: Journal of Hematology & Oncology 2019 12:36
    Content type: Research Published on:

  42. Extranodal NK/T cell lymphoma, nasal type (ENKTL) is an aggressive malignancy with a dismal prognosis. Although l-asparaginase-based chemotherapy has resulted in improved response rates, relapse occurs in up to 5...

    Authors: Sanjay de Mel, Susan Swee-Shan Hue, Anand D. Jeyasekharan, Wee-Joo Chng and Siok-Bian Ng
    Citation: Journal of Hematology & Oncology 2019 12:33
    Content type: Review Published on:

  44. Ferroptosis is a novel type of cell death with distinct properties and recognizing functions involved in physical conditions or various diseases including cancers. The fast-growing studies of ferroptosis in ca...

    Authors: Yanhua Mou, Jun Wang, Jinchun Wu, Dan He, Chunfang Zhang, Chaojun Duan and Bin Li
    Citation: Journal of Hematology & Oncology 2019 12:34
    Content type: Review Published on:

  45. Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damaging response (DDR) has an established role in disease pathobiology. Indeed, a deregulation of DNA repair pathways may contr...

    Authors: Maria Cucè, Maria Eugenia Gallo Cantafio, Maria Anna Siciliano, Caterina Riillo, Daniele Caracciolo, Francesca Scionti, Nicoletta Staropoli, Valeria Zuccalà, Lorenza Maltese, Anna Di Vito, Katia Grillone, Vito Barbieri, Mariamena Arbitrio, Maria Teresa Di Martino, Marco Rossi, Nicola Amodio…
    Citation: Journal of Hematology & Oncology 2019 12:32
    Content type: Research Published on:

  46. Myeloid-derived suppressor cells (MDSCs) are proposed to control graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the definition of human MDSCs has n...

    Authors: Ke Wang, Meng Lv, Ying-Jun Chang, Xiang-Yu Zhao, Xiao-Su Zhao, Yuan-Yuan Zhang, Yu-Qian Sun, Zhi-Dong Wang, Pan Suo, Yang Zhou, Dan Liu, Shu-Zhen Zhai, Yan Hong, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu…
    Citation: Journal of Hematology & Oncology 2019 12:31
    Content type: Research Published on:

  47. Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsi...

    Authors: Marion Wobser, Alexandra Weber, Amelie Glunz, Saskia Tauch, Kristina Seitz, Tobias Butelmann, Sonja Hesbacher, Matthias Goebeler, René Bartz, Hella Kohlhof, David Schrama and Roland Houben
    Citation: Journal of Hematology & Oncology 2019 12:30
    Content type: Research Published on:

  48. Childhood medulloblastomas (MB) are heterogeneous and are divided into four molecular subgroups. The provisional non-wingless-activated (WNT)/non-sonic hedgehog-activated (SHH) category combining group 3 and g...

    Authors: Otília Menyhárt, Felice Giangaspero and Balázs Győrffy
    Citation: Journal of Hematology & Oncology 2019 12:29
    Content type: Review Published on:

  49. Natural killer T cell lymphoma (NKTL) is an aggressive disease with very poor treatment outcomes in the advanced stages. With chemotherapy, initial response rates to treatment are high but responses are short ...

    Authors: Nagavalli Somasundaram, Jing Quan Lim, Choon Kiat Ong and Soon Thye Lim
    Citation: Journal of Hematology & Oncology 2019 12:28
    Content type: Review Published on:

  50. Angiogenesis has always been the topic of major scientific interest in the field of malignant tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by several mechanisms, includin...

    Authors: Shuang Qin, Anping Li, Ming Yi, Shengnan Yu, Mingsheng Zhang and Kongming Wu
    Citation: Journal of Hematology & Oncology 2019 12:27
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us